Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder

P. Pronzato, M. Landucci, F. Vaira, A. Vigani, G. Bertelli

Research output: Contribution to journalArticle

Abstract

Twenty outpatients with locally advanced (inoperable) or metastatic transitional cell carcinomas of the bladder were treated with carboplatin (300 mg/m2 i.v., day 1) + methotrexate (40 mg/m2 days 1 and 8) + vinblastine (6 mg/m2 days 1 and 8) (CaMV), every 4 weeks. One patient died of disease progression before completing at least 2 cycles of chemotherapy. Seven patients (35%) obtained a partial response; 8 had disease stabilization (40%) and 4 progressed (20%). Median duration of response was 3 months (range: 3-9), and median overall survival was 12+ months (range: 1-18+). None of the patients suffered grade IV toxicities, and no nephro-, neuro-, or ototoxicity was observed.

Original languageEnglish
Pages (from-to)223-225
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume18
Issue number3
Publication statusPublished - 1995

Keywords

  • Bladder cancer
  • Carboplatin, methotrexate, vinblastine (CaMV) combination
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Carboplatin, methotrexate, and vinblastine in outpatients with advanced transitional cell carcinoma of the bladder'. Together they form a unique fingerprint.

  • Cite this